ES2706317T3 - Nanopartícula de cambio de fase - Google Patents

Nanopartícula de cambio de fase Download PDF

Info

Publication number
ES2706317T3
ES2706317T3 ES15823030T ES15823030T ES2706317T3 ES 2706317 T3 ES2706317 T3 ES 2706317T3 ES 15823030 T ES15823030 T ES 15823030T ES 15823030 T ES15823030 T ES 15823030T ES 2706317 T3 ES2706317 T3 ES 2706317T3
Authority
ES
Spain
Prior art keywords
nanoparticle
nanospheres
phase change
subject
outer layer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15823030T
Other languages
English (en)
Spanish (es)
Inventor
Raphael Hof
Raz Khandadash
Ella Fremder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NEW PHASE Ltd
Original Assignee
NEW PHASE Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NEW PHASE Ltd filed Critical NEW PHASE Ltd
Application granted granted Critical
Publication of ES2706317T3 publication Critical patent/ES2706317T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/40—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals
    • A61N1/403—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals for thermotherapy, e.g. hyperthermia
    • A61N1/406—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals for thermotherapy, e.g. hyperthermia using implantable thermoseeds or injected particles for localized hyperthermia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES15823030T 2014-11-25 2015-11-25 Nanopartícula de cambio de fase Active ES2706317T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462083978P 2014-11-25 2014-11-25
PCT/IL2015/051146 WO2016084082A1 (en) 2014-11-25 2015-11-25 Phase-change nanoparticle

Publications (1)

Publication Number Publication Date
ES2706317T3 true ES2706317T3 (es) 2019-03-28

Family

ID=55080144

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15823030T Active ES2706317T3 (es) 2014-11-25 2015-11-25 Nanopartícula de cambio de fase

Country Status (7)

Country Link
US (2) US9872902B2 (zh)
EP (1) EP3226819B1 (zh)
CN (2) CN107206082B (zh)
CA (1) CA2968648C (zh)
ES (1) ES2706317T3 (zh)
IL (1) IL252488B (zh)
WO (1) WO2016084082A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5706420B2 (ja) 2009-08-24 2015-04-22 ニュー フェーズ リミテッド 相変化材料および形状変化材料
CN107206082B (zh) 2014-11-25 2022-01-11 纽菲斯有限公司 相变纳米粒子
CN110536701A (zh) * 2017-02-22 2019-12-03 纽菲斯有限公司 相变纳米微粒
CN111840810B (zh) * 2020-07-27 2022-03-01 哈尔滨工业大学 一种基于光学相变纳米颗粒的生物组织温度场被动调控方法
DE102022115394A1 (de) * 2022-06-21 2023-12-21 Rheinisch-Westfälische Technische Hochschule (Rwth) Aachen Implantat und Anordnung aufweisend eine Strahlungsquelle und ein Implantat

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4106488A (en) 1974-08-20 1978-08-15 Robert Thomas Gordon Cancer treatment method
US4096616A (en) 1976-10-28 1978-06-27 General Electric Company Method of manufacturing a concentric tube heat exchanger
US4204573A (en) 1977-05-09 1980-05-27 Pvi Industries, Inc. Heat exchanger with concentric flow tubes
US4392040A (en) 1981-01-09 1983-07-05 Rand Robert W Induction heating apparatus for use in causing necrosis of neoplasm
US4569836A (en) 1981-08-27 1986-02-11 Gordon Robert T Cancer treatment by intracellular hyperthermia
US4440217A (en) 1982-06-10 1984-04-03 Stieler Scott M Counterflow heat exchanger
US4747826A (en) 1983-06-08 1988-05-31 University Of Pittsburgh Rapid venous infusion system
US4678460A (en) 1985-02-11 1987-07-07 Rosner Mark S Portable rapid massive parenteral fluid warming and infusion apparatus
US4983159A (en) 1985-03-25 1991-01-08 Rand Robert W Inductive heating process for use in causing necrosis of neoplasms at selective frequencies
US5003991A (en) 1987-03-31 1991-04-02 Olympus Optical Co., Ltd. Hyperthermia apparatus
US5153827A (en) 1989-01-30 1992-10-06 Omni-Flow, Inc. An infusion management and pumping system having an alarm handling system
JPH03178668A (ja) 1989-12-06 1991-08-02 Senko Ika Kogyo Kk 熱交換器
DE69225043T2 (de) 1991-11-20 1998-09-03 Riken Kk Injizierbares Pulver zur Behandlung von Krebs
US5217363A (en) 1992-06-03 1993-06-08 Gaz Metropolitan & Co., Ltd. And Partnership Air-cooled oxygen gas burner assembly
US5318557A (en) 1992-07-13 1994-06-07 Elan Medical Technologies Limited Medication administering device
US5964744A (en) 1993-01-04 1999-10-12 Menlo Care, Inc. Polymeric medical device systems having shape memory
US5716410A (en) 1993-04-30 1998-02-10 Scimed Life Systems, Inc. Temporary stent and method of use
US5385540A (en) 1993-05-26 1995-01-31 Quest Medical, Inc. Cardioplegia delivery system
IL108832A (en) 1994-03-03 1999-12-31 Medinol Ltd Urological stent and positioning device for it
US5545210A (en) 1994-09-22 1996-08-13 Advanced Coronary Technology, Inc. Method of implanting a permanent shape memory alloy stent
US6059810A (en) 1995-05-10 2000-05-09 Scimed Life Systems, Inc. Endovascular stent and method
US5658234A (en) 1995-07-24 1997-08-19 J. D. Technologies, Inc. Method for treating tumors
EP0876169A1 (en) 1996-01-18 1998-11-11 Medtronic, Inc. Mesh spacer for heat exchanger
US5830179A (en) 1996-04-09 1998-11-03 Endocare, Inc. Urological stent therapy system and method
US6072154A (en) 1996-09-05 2000-06-06 Medtronic, Inc. Selectively activated shape memory device
US6451044B1 (en) 1996-09-20 2002-09-17 Board Of Regents, The University Of Texas System Method and apparatus for heating inflammed tissue
US5984893A (en) 1997-03-27 1999-11-16 Ward; Roger T. Blood infusion control system
US7041941B2 (en) 1997-04-07 2006-05-09 Patented Medical Solutions, Llc Medical item thermal treatment systems and method of monitoring medical items for compliance with prescribed requirements
DE19745890C1 (de) 1997-10-17 1999-03-25 Inst Physikalische Hochtech Ev Marker für eine Darm-Diagnostik und Darm-Therapie
US6120534A (en) 1997-10-29 2000-09-19 Ruiz; Carlos E. Endoluminal prosthesis having adjustable constriction
US6379378B1 (en) 2000-03-03 2002-04-30 Innercool Therapies, Inc. Lumen design for catheter
US7235096B1 (en) 1998-08-25 2007-06-26 Tricardia, Llc Implantable device for promoting repair of a body lumen
US6585692B1 (en) 1999-02-19 2003-07-01 Alsius Corporation Method and system for patient temperature management and central venous access
DE19921088C2 (de) 1999-04-30 2003-08-07 Magforce Applic Gmbh Stent zur Offenhaltung gangartiger Strukturen
US6554791B1 (en) 1999-09-29 2003-04-29 Smisson-Cartledge Biomedical, Llc Rapid infusion system
IL153753A0 (en) 2002-12-30 2003-07-06 Neovasc Medical Ltd Varying-diameter vascular implant and balloon
US7640062B2 (en) 2000-05-08 2009-12-29 Brainsgate Ltd. Methods and systems for management of alzheimer's disease
US7146209B2 (en) 2000-05-08 2006-12-05 Brainsgate, Ltd. Stimulation for treating eye pathologies
JP4311904B2 (ja) 2000-05-08 2009-08-12 ブレインスゲート リミテッド 血液脳関門及び脳血流の性質を改善するための翼口蓋神経節の刺激方法及び装置
US7117033B2 (en) 2000-05-08 2006-10-03 Brainsgate, Ltd. Stimulation for acute conditions
US6805711B2 (en) 2000-06-02 2004-10-19 3F Therapeutics, Inc. Expandable medical implant and percutaneous delivery
WO2002000145A1 (en) 2000-06-26 2002-01-03 BVBA Flux Medical Systems Therapeutic Method and apparatus for external non-invasive heating of metallic implants by use of alternating magnetic fields
US8372139B2 (en) 2001-02-14 2013-02-12 Advanced Bio Prosthetic Surfaces, Ltd. In vivo sensor and method of making same
US6768921B2 (en) 2000-12-28 2004-07-27 Z-Tech (Canada) Inc. Electrical impedance method and apparatus for detecting and diagnosing diseases
US6390185B1 (en) 2001-03-06 2002-05-21 Richard A. Proeschel Annular flow concentric tube recuperator
DE10113659B4 (de) 2001-03-21 2006-10-26 Triton BioSystems Inc., Chelmsford Metallischer medizinischer Stent
US6746439B2 (en) 2001-04-19 2004-06-08 Jay Alan Lenker Method and apparatus for fluid administration with distributed heating
US7074175B2 (en) 2001-07-25 2006-07-11 Erik Schroeder Handy Thermotherapy via targeted delivery of nanoscale magnetic particles
US7731648B2 (en) 2001-07-25 2010-06-08 Aduro Biotech Magnetic nanoscale particle compositions, and therapeutic methods related thereto
DK1450727T3 (da) 2001-10-04 2010-10-18 Neovasc Medical Ltd Strømreducerende implantat
US7048756B2 (en) 2002-01-18 2006-05-23 Apasara Medical Corporation System, method and apparatus for evaluating tissue temperature
AU2002226251A1 (en) 2002-02-07 2003-09-02 Medela Ag Breast cap
US8709488B2 (en) 2002-02-14 2014-04-29 Gholam A. Peyman Method and composition for hyperthermally treating cells
US7684859B2 (en) 2002-04-25 2010-03-23 Brainsgate Ltd. Stimulation of the OTIC ganglion for treating medical conditions
EP1521614A2 (en) 2002-06-14 2005-04-13 Brainsgate Ltd. Methods and systems for management of alzheimer's disease
TWI313188B (en) 2002-09-12 2009-08-11 Shell Int Research Catalytic conversion of an organic carbonate
US20040059385A1 (en) 2002-09-25 2004-03-25 Yu Tsung I. Low frequency assistor for electric-stimulating breast acupuncture point portions of a human body
US7112273B2 (en) 2002-09-27 2006-09-26 Nxstage Medical, Inc. Volumetric fluid balance control for extracorporeal blood treatment
KR20050083750A (ko) 2002-10-11 2005-08-26 디포메드 디벨롭먼트 리미티드 위-체류성 레보도파 전달 형태
US7560160B2 (en) 2002-11-25 2009-07-14 Materials Modification, Inc. Multifunctional particulate material, fluid, and composition
JP2006517827A (ja) 2003-01-29 2006-08-03 イー−ピル・ファーマ・リミテッド 胃腸管内における活性薬物の送達
AU2003904086A0 (en) 2003-08-04 2003-08-21 Cochlear Limited Implant battery short circuit protection
US20050074506A1 (en) 2003-10-02 2005-04-07 Brainsgate Ltd. Targeted release of nitric oxide in the CNS circulation for modulating the BBB and treating disorders
US7270910B2 (en) 2003-10-03 2007-09-18 Black & Decker Inc. Thermal management systems for battery packs
US20050090732A1 (en) 2003-10-28 2005-04-28 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles
US9040090B2 (en) * 2003-12-19 2015-05-26 The University Of North Carolina At Chapel Hill Isolated and fixed micro and nano structures and methods thereof
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
US8010189B2 (en) 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
US7627381B2 (en) 2004-05-07 2009-12-01 Therm Med, Llc Systems and methods for combined RF-induced hyperthermia and radioimmunotherapy
US7510555B2 (en) 2004-05-07 2009-03-31 Therm Med, Llc Enhanced systems and methods for RF-induced hyperthermia
US20050283327A1 (en) 2004-06-21 2005-12-22 Bowman Catherine M Breast feeding monitoring device and method
US7510577B2 (en) 2004-06-29 2009-03-31 Micardia Corporation Adjustable cardiac valve implant with ferromagnetic material
US20060083694A1 (en) 2004-08-07 2006-04-20 Cabot Corporation Multi-component particles comprising inorganic nanoparticles distributed in an organic matrix and processes for making and using same
CN101115527A (zh) 2004-12-09 2008-01-30 帕洛玛医疗技术公司 具有传热机构的口腔器具
US20060276882A1 (en) 2005-04-11 2006-12-07 Cook Incorporated Medical device including remodelable material attached to frame
US7357815B2 (en) 2005-04-21 2008-04-15 Micardia Corporation Dynamically adjustable implants and methods for reshaping tissue
CN100336598C (zh) 2005-06-13 2007-09-12 天津大学 自换热型催化剂评价反应器
TWI314465B (en) * 2005-12-30 2009-09-11 Ind Tech Res Inst Thermosensitive nanostructure for hyperthermia treatment
US8404341B2 (en) * 2006-01-26 2013-03-26 Outlast Technologies, LLC Microcapsules and other containment structures for articles incorporating functional polymeric phase change materials
GB0605672D0 (en) 2006-03-22 2006-05-03 Univ Keele Indirect heating
US7919184B2 (en) 2006-08-21 2011-04-05 Mohapatra Satish C Hybrid nanoparticles
US8518870B2 (en) 2007-02-19 2013-08-27 The Board Of Regents Of The University Of Oklahoma Compositions and methods for cancer treatment using targeted carbon nanotubes
WO2008148014A2 (en) 2007-05-23 2008-12-04 C.R. Bard, Inc. Polymer coated stent
CN101343529B (zh) * 2007-07-13 2010-09-01 中国科学院大连化学物理研究所 一种复合相变材料的制备方法
ES2320837B1 (es) 2007-07-26 2010-03-04 Consejo Superior De Investigaciones Cientificas Dispositivo de hipertermia y su utilizacion con nanoparticulas.
US20090082832A1 (en) 2007-09-25 2009-03-26 Boston Scientific Neuromodulation Corporation Thermal Management of Implantable Medical Devices
US20130078288A1 (en) 2007-11-21 2013-03-28 Chun Ho Yu Method of Treating Cancer
US8326426B2 (en) 2009-04-03 2012-12-04 Enteromedics, Inc. Implantable device with heat storage
JP5706420B2 (ja) 2009-08-24 2015-04-22 ニュー フェーズ リミテッド 相変化材料および形状変化材料
US20110195526A1 (en) 2010-02-11 2011-08-11 University Of Central Florida Research Foundation Thermo-probes, methods of making thermo-probes, and methods of detection using thermo-probes
CN101836915B (zh) * 2010-03-12 2012-07-04 重庆大学 热物理治疗中对正常组织进行热防护的磁性相变微胶囊
US8197471B1 (en) * 2011-02-14 2012-06-12 Samuel Harry Tersigni Core-excited nanoparticles and methods of their use in the diagnosis and treatment of disease
CN102172411B (zh) * 2011-03-04 2013-08-21 中国人民解放军第二军医大学 具有靶向mr显像和光热疗性能的纳米复合物粒子及其制备方法
CN102198086B (zh) * 2011-05-27 2012-12-26 上海交通大学医学院 一种固相纳米胶束及其制备方法
WO2013056092A1 (en) * 2011-10-12 2013-04-18 Case Western Reserve University Multi-component nanochains
WO2014055539A1 (en) * 2012-10-01 2014-04-10 University Of Washington Through Its Center For Commercialization Nanoparticle emulsions
CN104127872B (zh) * 2014-07-29 2016-05-25 北京福纳康生物技术有限公司 金属富勒烯单晶纳米颗粒在制备特异性肿瘤血管阻断剂中的应用
CN107206082B (zh) 2014-11-25 2022-01-11 纽菲斯有限公司 相变纳米粒子

Also Published As

Publication number Publication date
CA2968648A1 (en) 2016-06-02
EP3226819B1 (en) 2018-10-24
US9872902B2 (en) 2018-01-23
WO2016084082A1 (en) 2016-06-02
CN107206082B (zh) 2022-01-11
IL252488A0 (en) 2017-07-31
CN107206082A (zh) 2017-09-26
CN114209830B (zh) 2023-12-22
IL252488B (en) 2021-02-28
US20180117154A1 (en) 2018-05-03
US10172939B2 (en) 2019-01-08
EP3226819A1 (en) 2017-10-11
CN114209830A (zh) 2022-03-22
CA2968648C (en) 2021-05-18
US20170209580A1 (en) 2017-07-27

Similar Documents

Publication Publication Date Title
ES2706317T3 (es) Nanopartícula de cambio de fase
Gil et al. Nanopharmacy: Inorganic nanoscale devices as vectors and active compounds
Parchur et al. Vascular interventional radiology-guided photothermal therapy of colorectal cancer liver metastasis with theranostic gold nanorods
Hussein et al. Recent advances in functional nanostructures as cancer photothermal therapy
Shen et al. CMCTS stabilized Fe 3 O 4 particles with extremely low toxicity as highly efficient near-infrared photothermal agents for in vivo tumor ablation
Ma et al. Cancer‐targeted nanotheranostics: recent advances and perspectives
Li et al. Research perspectives: gold nanoparticles in cancer theranostics
Kim et al. Doxorubicin-fucoidan-gold nanoparticles composite for dual-chemo-photothermal treatment on eye tumors
Li et al. Multifunctional bismuth selenide nanocomposites for antitumor thermo-chemotherapy and imaging
Fan et al. Theranostic nanomedicine for cancer detection and treatment
Glazer et al. Non-invasive radiofrequency ablation of malignancies mediated by quantum dots, gold nanoparticles and carbon nanotubes
Frazier et al. Hyperthermia approaches for enhanced delivery of nanomedicines to solid tumors
US20020159951A1 (en) Novel targeted compositions for diagnostic and therapeutic use
AU2005251499A1 (en) Activatable particles, preparations and uses.
Gayathri et al. Gadolinium oxide nanoparticles for magnetic resonance imaging and cancer theranostics
BR112012000530B1 (pt) uso de uma população de nanopartículas de ouro
Levi-Polyachenko et al. Clinical relevance of nanoparticle induced hyperthermia for drug delivery and treatment of abdominal cancers
Dabbagh et al. Triggering mechanisms of thermosensitive nanoparticles under hyperthermia condition
Yadollahpour et al. Magnetic nanoparticle based hyperthermia: A review of the physiochemical properties and synthesis methods
Chen et al. Manganese (iii)-chelated porphyrin microbubbles for enhanced ultrasound/MR bimodal tumor imaging through ultrasound-mediated micro-to-nano conversion
Oraevsky Gold and silver nanoparticles as contrast agents for optoacoustic tomography
ES2378365T3 (es) Micropartículas para hipertermia dirigida selectivamente
Caizer Magnetic/Superparamagnetic hyperthermia as an effective noninvasive alternative method for therapy of malignant tumors
US20200054886A1 (en) Phase-change nanoparticle
Riaz et al. Nanotechnology: Next generation war against cancer